Gabapentin for treatment of neonatal abstinence syndrome in patients with or without perinatal gabapentin exposure

Résumé fourni par la source

Abstract Objective To determine the effect of gabapentin on neonatal abstinence syndrome (NAS)-related neurologic and/or feeding symptoms. Study Design: Retrospective case series involving thirteen infants who received gabapentin for NAS Result Gabapentin 5 mg/kg every 8 to 12 hours was initiated, and three (23%) patients required dose escalation. Median time from initiation to discharge was 8 days (range: 2–15) and length of stay was 19 days (range: 13–45 days). Eight patients required gavage feeds, and showed oral feeding improvement. All patients were discharged home with gabapentin and weaned off in the outpatient setting. Conclusion Although there is limited experience with gabapentin for NAS, it may be beneficial for managing symptoms not controlled by other treatment modalities, regardless of prenatal exposure. No side effects were noted and oral feeding was improved. Prospective randomized studies are needed to confirm the efficacy and safety of gabapentin in the treatment of neonatal abstinence syndrome.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.